Identification of gaps in the current allergic rhinitis guidelines and how these can be filled

Benzer Materyaller

• A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
  Yazar:: Hellings, Peter, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
  Yazar:: Scadding, Glenis, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
  Yazar:: Price, David, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
  Yazar:: Hellings, Peter, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
  Yazar:: Bousquet, Jean, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)